



Pharmacy and Therapeutics Committee Meeting

Agenda

Wednesday, July 16, 2025

7:30 – 9:30 am

San Francisco Health Plan
50 Beale St.
San Francisco, CA, 94105
City Hall Conference Room

Microsoft Teams Meeting

Join on your computer, mobile app or room device

[Join the meeting now](#)

Meeting ID: 286 657 079 426

Passcode: Gv29V7cd

Or call in (audio only)

[+1 323-475-1528,,238593003#](#)

United States, Los Angeles

Phone conference ID: 238 593 003#

**To arrange for public building access, please contact
Luke Nelson at 415-615-4269**

-
- 1) Call to order – non-voting item (est. time 5 minutes)
Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan
 - Attendance/Quorum
 - Agenda overview
 - 2) Review and Approval of April 16, 2025, P&T minutes – voting item (est. time 3 minutes)
Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan
 - 3) Informational Updates – non-voting item (est. time 10 minutes)
Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan
Brian Ellsworth, PharmD, Pharmacy Director, San Francisco Health Plan
 - D-SNP updates
 - 4) Annual Pharmacy Policies and Procedures (P&Ps) Review – **voting item** (est. time 5 minutes)
Sue Chan, Pharmacy Compliance Program Manager, San Francisco Health Plan
 - Pharm-07 Emergency Medication Supply
 - Pharm-11 Member Reimbursement for Pharmacy Services
 - Pharm-14 Pharmacy Drug Utilization Review (DUR) Program
 - Pharm-16 Pharmacy System User Access
 - Pharm-17 DSNP Part D Transition Policy
- ADJOURN TO CLOSED SESSION**
Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan
- 5) Review and Approval of Formulary Interim Changes – **voting item** (est. time 3 minutes)
Eileen Kim, PharmD, Clinical Pharmacist, San Francisco Health Plan
 - 6) Review and Approval of Prior Authorization Criteria Interim Changes – **voting item** (est. time 10 minutes)
Eileen Kim, PharmD, Clinical Pharmacist, San Francisco Health Plan
 - 7) Discussion and Recommendations for Changes to SFHP Formulary and Prior Authorization Criteria and Drug Utilization Review Reports for Select Drug Classes - **voting item** (est. time 55 mins)
Eileen Kim, PharmD, Clinical Pharmacist, San Francisco Health Plan
Katie Vo, PharmD, Clinical Pharmacist, San Francisco Health Plan
Ai Quynh Nguyen, PharmD, Pharmacist Account Manager, Prime Therapeutics



Pharmacy and Therapeutics Committee Meeting

Agenda

- Endocrinology
 - Anti-Obesity Medications Class Review
 - Tryngolza™ Monograph
 - Gastroenterology
 - Iqirvo® and Livdelzi® Monograph
 - Nephrology
 - CKD and MBD Class Review
 - Pain
 - Journavx® Monograph
 - Psychiatry
 - Attention Deficit Hyperactivity Disorder Class Review
- 8) DUR Program Updates, Reports, and/or Educational Items – non-voting item (est. time 15 minutes)
Katie Vo, PharmD, Clinical Pharmacist, San Francisco Health Plan
- Prime/Magellan Rx Retrospective DUR Quarterly Activities 1Q2025
 - Asthma Letter
 - Migraine Letter
 - Opioids Letter
 - Fraud, Waste and Abuse (FWA) DUR Report: Multiple Providers and Multiple Pharmacies
- RECONVENE IN OPEN SESSION**
Summary of Closed Session – non-voting item (est. time 4 minutes)
Steve O'Brien, MD, Chief Medical Officer, San Francisco Health Plan
- 9) Appendix: Prime Therapeutics Pipeline Report– non-voting item (est. time 10 minutes)
Ai Quynh Nguyen, PharmD, Pharmacist Account Manager, Prime Therapeutics
- 10) Adjournment
- Upcoming P&T Committee meeting dates
 - **Wednesday, October 15, 2025**
 - **Wednesday, January 21, 2026**
 - **Wednesday, April 8, 2026**
 - **Wednesday, July 15, 2026**